vs
Side-by-side financial comparison of Foresight Autonomous Holdings Ltd. (FRSX) and CytoMed Therapeutics Ltd (GDTC). Click either name above to swap in a different company.
Foresight Autonomous Holdings Ltd. is the larger business by last-quarter revenue ($128.0K vs $115.4K, roughly 1.1× CytoMed Therapeutics Ltd). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-2.6M).
Foresight Autonomous Holdings Ltd. develops and markets advanced perception systems for the autonomous driving and automotive safety sectors. Its core offerings include multi-sensor vision solutions combining thermal imaging, visible light and AI analytics to enhance obstacle detection, collision avoidance and navigation reliability for passenger cars, commercial fleets and off-road industrial equipment, with operations spanning North America, Europe and Asia.
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
FRSX vs GDTC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.0K | $115.4K |
| Net Profit | $-2.8M | — |
| Gross Margin | 67.2% | — |
| Operating Margin | -2305.5% | — |
| Net Margin | -2155.5% | — |
| Revenue YoY | 4.1% | — |
| Net Profit YoY | 13.0% | — |
| EPS (diluted) | $-0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $128.0K | $115.4K | ||
| Q2 24 | $123.0K | — | ||
| Q2 22 | $213.0K | — |
| Q2 25 | $-2.8M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q2 22 | $-10.1M | — |
| Q2 25 | 67.2% | — | ||
| Q2 24 | 69.1% | — | ||
| Q2 22 | 57.7% | — |
| Q2 25 | -2305.5% | — | ||
| Q2 24 | -2602.4% | — | ||
| Q2 22 | -1936.6% | — |
| Q2 25 | -2155.5% | — | ||
| Q2 24 | -2578.9% | — | ||
| Q2 22 | -4749.3% | — |
| Q2 25 | $-0.01 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q2 22 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | — |
| Total Assets | $8.5M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $6.4M | — | ||
| Q2 24 | $12.0M | — | ||
| Q2 22 | $35.5M | — |
| Q2 25 | $5.9M | — | ||
| Q2 24 | $10.9M | — | ||
| Q2 22 | $37.1M | — |
| Q2 25 | $8.5M | — | ||
| Q2 24 | $15.4M | — | ||
| Q2 22 | $41.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-855.3K |
| Free Cash FlowOCF − Capex | $-2.6M | $-855.4K |
| FCF MarginFCF / Revenue | -2041.4% | -741.5% |
| Capex IntensityCapex / Revenue | 2.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-2.6M | $-855.3K | ||
| Q2 24 | $-2.5M | — | ||
| Q2 22 | $-3.3M | — |
| Q2 25 | $-2.6M | $-855.4K | ||
| Q2 24 | $-2.6M | — | ||
| Q2 22 | $-3.3M | — |
| Q2 25 | -2041.4% | -741.5% | ||
| Q2 24 | -2080.5% | — | ||
| Q2 22 | -1571.8% | — |
| Q2 25 | 2.3% | 0.0% | ||
| Q2 24 | 17.1% | — | ||
| Q2 22 | 32.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
